Investors are increasingly turning their attention to the medical technology sector, which has shown considerable growth and resilience. This article highlights ten medical technology stocks that offer promising investment opportunities as the industry continues to evolve and integrate advanced technologies such as artificial intelligence (AI) and digital health solutions.
The global MedTech market is projected to reach a value of approximately $584 billion by 2025, according to Ernst & Young. This growth trajectory follows seven consecutive years of top-line growth. Another report from Future Market Insights Inc. estimates the market at $549 billion and anticipates it will expand to $853 billion by 2035, reflecting an annual growth rate of 4.5%. Key drivers include the integration of AI technologies, which enhance diagnostic accuracy and improve patient care.
Market Resilience Amid Economic Challenges
Despite a challenging global trade environment and fluctuating macroeconomic conditions, industry experts remain optimistic about the MedTech sector’s performance. Both Ernst & Young and Future Market Insights emphasize the importance of digital health and AI as stabilizing factors. Robust investment activity and rising revenues are also contributing to the sector’s resilience.
Notably, Bob Lang, chief options analyst at Explosive Options, suggests that healthcare is becoming an attractive alternative for investors fatigued by the broader tech sector. He expressed that many investors are seeking better-performing stocks, with healthcare emerging as a strong contender.
Investors should consider the following ten standout medical technology stocks, based on rigorous analysis of hedge fund ownership and projected upside potential.
Top 10 Medical Technology Stocks to Watch
10. ResMed Inc. (NYSE:RMD)
– Number of Hedge Fund Holdings: 43
– Projected Stock Upside: 27.97%
ResMed Inc. has received positive attention following its Q2 fiscal 2026 results, which exceeded revenue expectations, particularly in its Masks & Accessories and Devices segments. Analysts from KeyBanc Capital Markets and RBC Capital Markets have raised their price targets, citing strong growth and improved profitability.
9. Globus Medical Inc. (NYSE:GMED)
– Number of Hedge Fund Holdings: 46
– Projected Stock Upside: 26.12%
Globus Medical recently upgraded its rating from Hold to Buy, following encouraging preliminary fourth-quarter revenue figures. Analysts expect margin expansion and improved organic revenue growth to bolster earnings in fiscal 2026.
8. STERIS plc (NYSE:STE)
– Number of Hedge Fund Holdings: 46
– Projected Stock Upside: 20.79%
STERIS reported a revenue increase of 7.1% year-over-year in its Q3 FY2026 results. Despite facing tariff costs, strong cash flow and demand across multiple business lines position STERIS favorably in the market.
7. Inspire Medical Systems Inc. (NYSE:INSP)
– Number of Hedge Fund Holdings: 48
– Projected Stock Upside: 80.22%
Despite recent challenges related to reimbursement changes, Inspire Medical Systems has continued to project revenue growth within the high single digits. Analysts remain optimistic about its long-term profitability.
6. IDEXX Laboratories Inc. (NASDAQ:IDXX)
– Number of Hedge Fund Holdings: 55
– Projected Stock Upside: 28.00%
IDEXX reported a robust Q4 2025, with revenue rising 14% to $1.09 billion. The company anticipates continued steady growth in 2026, despite some headwinds affecting pet visits.
5. Insulet Corporation (NASDAQ:PODD)
– Number of Hedge Fund Holdings: 56
– Projected Stock Upside: 57.79%
Insulet’s Omnipod 5 Automated Insulin Delivery system is now available in the Middle East, marking a significant expansion. The company expects this system to simplify diabetes management for users.
4. GE HealthCare Technologies Inc. (NASDAQ:GEHC)
– Number of Hedge Fund Holdings: 58
– Projected Stock Upside: 20.79%
GE HealthCare recently launched ReadyFix, a remote fleet management solution designed to optimize the performance of connected medical devices. This innovation aims to enhance operational efficiency in healthcare settings.
3. Edwards Lifesciences Corporation (NYSE:EW)
– Number of Hedge Fund Holdings: 64
– Projected Stock Upside: 30.82%
Following strong Q4 2025 results, Edwards Lifesciences maintained its positive outlook for 2026. The company’s transcatheter aortic valve replacement sales continue to drive growth.
2. DexCom Inc. (NASDAQ:DXCM)
– Number of Hedge Fund Holdings: 71
– Projected Stock Upside: 30.61%
DexCom reported a strong quarterly revenue of $1.26 billion, driven by robust sales of its glucose monitoring systems. The company aims to expand its market share further in 2026.
1. Boston Scientific Corporation (NYSE:BSX)
– Number of Hedge Fund Holdings: 102
– Projected Stock Upside: 41.66%
Despite a recent price target adjustment, Boston Scientific’s solid quarterly performance indicates significant growth potential. The upcoming CHAMPION‐AF trial results could further influence the company’s market position.
As investors seek promising opportunities within the MedTech sector, these ten stocks represent a blend of innovation, strong financials, and growth potential. With the integration of advanced technologies and a resilient market outlook, the medical technology industry is poised for continued expansion in the coming years.
